loader
Please Wait
Applying Filters...

Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    List of All Manufacturers & Suppliers for 206334 Licensing, EU CTD Dossiers, Marketing Authorizations, Finished Dosage Formulations listed on PharmaCompass.com

    Client Virtual Booth
    Menu

    Melinta Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Send me more info on How To Grow My Business Digitally?

    Left Arrow
    Right Arrow
    Filters Filter
    Cross PopUp
    FILTER :

    filter

    01 ORITAVANCIN DIPHOSPHATE (1)

    filter

    01 MELINTA THERAP (1)

    filter

    01 POWDER;INTRAVENOUS (1)

    filter

    01 EQ 400MG BASE/VIAL (1)

    filter

    01 USA (1)

    ListList of Suppliers
    refresh Reset Filter
    refresh Reset Filter
    product-page Supplier Virtual Booth
    price-trend Ask Us
    Contact Supplier
      Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
      Post an Enquiry Post an Enquiry
      Flag U.S.A
      Virtual Booth Virtual Booth
      Digital Content Digital Content

      Oritavancin Diphosphate

      PDF Supplier PDF
      URL Supplier Web Content
      POWDER;INTRAVENOUS
      EQ 400MG BASE/VIAL
      ORBACTIV
      USA
      206334
      2014-08-06
      RX
      ASK
      US
      PHARMACOMPASS
      Upload
      your Marketing & Sales content

      Looking for CTD TGA MCC DOSSIER APPLICATION 206334

      Looking for CTD TGA MCC DOSSIER APPLICATION 206334 1

      19

      Melinta Therapeutics, based in U.S.A, is a pharmaceutical company.

      One of their notable products is ORITAVANCIN DIPHOSPHATE, with a corresponding application number 206334 and regulatory information .

      proudly manufactured in the

      approval since 2014-08-06

      Melinta Therapeutics's ORBACTIV POWDER;INTRAVENOUS, medication with EQ 400MG BASE/VIAL of ORITAVANCIN DIPHOSPHATE.

      Post Enquiry
      POST ENQUIRY